Industries de la santé
Glioblastoma Treatment Hopes Turn to Combining Peptide Vaccines with Immuno-Oncology Products, say GlobalData Analysts
17 Mars 2016
LONDON, UK (GlobalData), 15 March 2016 - The termination of Celldex’s Phase III trial assessing its peptide-based vaccine therapy, Rintega, in newly-diagnosed glioblastoma patients, represents a blow to the treatment space as hopes for improved therapies turn instead to Opdivo and drugs combining peptide vaccines with immuno-oncology products, according to analysts with research and... |Plus d'articles...
- Teradata et Knowledgent s'associent pour aider les entreprises du secteur de la santé à mieux évaluer les risques liés aux patients
- Burgeoning Global Telehealth Market Could Deliver Huge Savings to Government Healthcare Budgets, says GBI Research
- Actinium Pharmaceuticals Selects Medpace Inc. as Clinical Research Organization for Pivotal Phase 3 Iomab-B Trial
- Amedica and Celling Biosciences to Collaborate on Biologically Enhanced Spinal Fusion Devices